Theranica and Dr Reddy’s have entered an exclusive agreement for the marketing and distribution of Nerivio in Europe.
The countries involved in the agreement include Austria, Czech Republic, Sweden, Switzerland and the UK, in addition to Germany, which was previously agreed.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Worn on the upper arm, the Nerivio device uses non-painful remote electrical modulation (REN) to activate the peripheral nerves. This stimulation prompts the transmission of signals that initiate a descending pain management mechanism known as conditioned pain modulation (CPM) within the brain to stop migraine pain and its related symptoms. The wearable device is self-administered and controlled by a smartphone app.
Each treatment lasts 45 minutes and is given every alternate day for prevention, or when a migraine attack begins for acute treatment.
The device received an expanded CE mark approval under MDR European regulation as a dual-use migraine treatment for adults and adolescents in August 2023.
Nerivio has been available by prescription in the US since 2020. It was initially used as an acute treatment and has been available as a preventative treatment since April 2023.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDr Reddy’s Laboratories Generics Europe CEO Patrick Aghanian said: “Dr Reddy’s commercial collaboration with Theranica perfectly aligns with our commitment to address unmet patient needs. We are excited to bring a drug-free migraine treatment option to European patients, which could make a difference to migraine patients’ quality of life.”
According to GlobalData analysis, wearable tech will become a $291bn industry by 2030.
